ArticleInvestigative ophthalmology & visual science2025
Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate short-term intraocular blood flow changes post-intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with neovascular age-related macular degeneration (nAMD), compare reductions across 4 agents (brolucizumab, faricimab, aflibercept 2 mg, and aflibercept 8 mg), and examine correlations between each agent's molar dose and the magnitude of 30-minute blood flow change. Methods: This retrospective series included 61 eyes with nAMD (15 treated with brolucizumab, 15 with faricimab, 15 with aflibercept 2 mg, and 16 with aflibercept 8 mg). Laser speckle flowgraphy quantified mean blur rate (MBR) at the optic nerve head vessels (ONH MBR-vessel) and choroid (CHOR MBR) before and 30 minutes post-injection. Percent changes (%ONH MBR-vessel, %CHOR MBR) were compared among groups, and correlations with molar dose were assessed. Results: In the aflibercept 8 mg group, the mean percent changes were -11.2% ± 11.2% for ONH MBR-vessel (P = 0.001) and -13.7% ± 7.5% for CHOR MBR (P < 0.001). Pairwise comparisons showed no significant differences in %ONH MBR-vessel between aflibercept 8 mg and other agents. The reduction in %CHOR MBR was significantly greater with aflibercept 8 mg than with aflibercept 2 mg (P = 0.019). Molar dose was not significantly correlated with %ONH MBR-vessel, whereas %CHOR MBR showed a significant negative association with molar dose (Spearman ρ = -0.395, P = 0.002). Conclusions: Aflibercept 8 mg produced a significant 30-minute reduction in ocular blood flow. Choroidal flow reduction was greater than with aflibercept 2 mg and negatively correlated with molar dose, suggesting a concentration-dependent hemodynamic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.